Whitney Tilson’s email to investors discussing Canada’s legal high, a business letdown; Tom Carroll on the cannabis sector; A startup fired its CEO for expensing $76,120 at Strip Clubs; Question No. 1 to ask before you marry someone.
1) Here’s a recent article in the New York Times about the crash in the Canadian cannabis sector: From Canada’s Legal High, a Business Letdown. Excerpt:
When Canada became the first major industrialized nation to legalize recreational marijuana, visions of billions of dollars in profits inspired growers, retailers and investors, sending the stock market soaring in a so-called green rush.
RGA Investment Advisor 2Q20 Commentary: The Tale of Two Markets
RGA Investment Advisor commentary for the second quarter ended July 2020, titled, "The Tale of Two Markets." Q2 2020 hedge fund letters, conferences and more In our Q1 2019 commentary we expressed how “COVID-19 will kick off one of the most profound reshaping of our world any of us will see in our lifetime,” accompanied Read More
However, unlike bitcoin and other cryptocurrencies – which are nothing but a techno-libertarian pump-and-dump scheme, so there is no price at which I would recommend them – the cannabis sector is very real and will grow enormously from here. Thus, my instinct is that investment opportunities are beginning to emerge in the sector.
To separate the legitimate stock ideas from the riffraff, I turned to my friend at Stansberry Research, Tom Carroll, who writes the Cannabis Capitalist newsletter.
Regular Empire Financial Daily readers will recognize Tom’s name. He spent nearly two decades as an analyst and managing director at Legg Mason and Stifel Financial. His background as both an award-winning stock-picker and his profound knowledge of the health care market make him well-qualified to analyze the cannabis industry and find undiscovered gems.
I asked Tom for an update on the sector yesterday, and he gave me permission to share the following thoughts:
We remain on the sidelines relative to the Canadian stocks. Their numbers are still abysmal and traditional valuation multiples can’t be calculated (other than price to sales) because of losses and restatements. However, given the hammering the stocks have taken, we are starting to sniff around. The one name I am warming to is OrganiGram (OGI). I haven’t recommended it yet, but it looks interesting.